[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100264914":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":7,"locations":11,"responsibleParty":22,"collaborators":7,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":28,"acronym":7,"eligibilityCriteria":29,"healthyVolunteers":26,"sex":30,"minAge":31,"maxAge":7,"enrollmentInfo":32,"targetDuration":35,"studyType":36,"phases":7,"briefSummary":37,"conditions":38,"keywords":7,"overallStatus":40,"whyStopped":7,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":49},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",null,[9],{"name":5,"affiliation":5,"role":10},"STUDY_DIRECTOR",[12],{"facility":13,"status":7,"city":14,"state":7,"zip":7,"country":15,"countryCode":7,"cosmosGeoPoint":16,"geoPoint":21,"contacts":7},"Local Institution","Seoul","South Korea",{"type":17,"coordinates":18},"Point",[19,20],126.9784,37.566,{"lat":20,"lon":19},{"type":23,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100264914","postmarketing-surveillance-of-the-safety-and-effectiveness-of-daclatasvir-and-asunaprevir-for-the-treatment-of-chronic-hcv-genotype-1b-infection-in-the-routine-clinical-practice-in-korea-100264914",false,"NCT02727933","Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea","Inclusion Criteria:\n\n* Patients with CHC genotype 1b and compensated liver disease, including cirrhotic patients\n* Eligible for treatment with Daklinza and Sunvepra as indicated in the locally approved prescribing information.\n\nExclusion Criteria:\n\n* Off-label use of Daklinza and Sunvepra\n* Patients with a contraindication for the use of Daklinza and Sunvepra as described in the locally approved prescribing information","ALL","19 Years",{"count":33,"type":34},1941,"ACTUAL","6 Years","OBSERVATIONAL","The primary objective of this study is to describe the safety of the combination of Daklinza (daclatasvir) and Sunvepra (asunaprevir) when used for the treatment of chronic hepatitis C (CHC) genotype 1b patients in real-life conditions when used according to its registered indications.",[39],"Hepatitis C","COMPLETED","2022-01-06",{"date":43,"type":34},"2022-01-21",{"date":45,"type":34},"2015-11-03",{"date":47,"type":34},"2020-07-05",{"name":5,"class":6},1]